Xeris Biopharma Holdings, Inc. XERS Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s other commercial liabilities?
- Xeris Biopharma Holdings, Inc. (XERS) reported other commercial liabilities of $32.29M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s other commercial liabilities changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s other commercial liabilities increased by 61.0% year-over-year, from $20.05M to $32.29M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s other commercial liabilities has grown at a 15.8% compound annual growth rate (CAGR), from $15.9M to $33.16M.